Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-068549
Filing Date
2025-05-12
Accepted
2025-05-12 07:10:32
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tngx-20250331.htm   iXBRL 10-Q 1762146
2 EX-31.1 tngx-ex31_1.htm EX-31.1 17686
3 EX-31.2 tngx-ex31_2.htm EX-31.2 17634
4 EX-32.1 tngx-ex32_1.htm EX-32.1 8551
5 EX-32.2 tngx-ex32_2.htm EX-32.2 8542
  Complete submission text file 0000950170-25-068549.txt   7437445

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tngx-20250331.xsd EX-101.SCH 965172
68 EXTRACTED XBRL INSTANCE DOCUMENT tngx-20250331_htm.xml XML 1371212
Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39485 | Film No.: 25932563
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)